Keywords: map, initiates, ph, iii, trial, asthma, product

MAP initiates Ph III trial of asthma product

Article | 14 January 2008

Print This

The USA's MAP Pharmaceuticals has initiated a Phase III clinical trial evaluating Unit Dose Budesonide, its proprietary nebulized version of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in